Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
F Aranda, E Vacchelli, A Eggermont, J Galon… - …, 2014 - Taylor & Francis
Immunostimulatory monoclonal antibodies (mAbs) exert antineoplastic effects by eliciting a
novel or reinstating a pre-existing antitumor immune response. Most often …
novel or reinstating a pre-existing antitumor immune response. Most often …
[引用][C] Trial Watch
F Aranda, E Vacchelli, F Obrist, A Eggermont… - …, 2014 - cir.nii.ac.jp
Trial Watch | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動
検索フォームへ移動 論文・データをさがす 大学図書館の本をさがす 日本の博士論文をさがす …
検索フォームへ移動 論文・データをさがす 大学図書館の本をさがす 日本の博士論文をさがす …
[HTML][HTML] Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
F Aranda, E Vacchelli, A Eggermont, J Galon… - …, 2014 - ncbi.nlm.nih.gov
Immunostimulatory monoclonal antibodies (mAbs) exert antineoplastic effects by eliciting a
novel or reinstating a pre-existing antitumor immune response. Most often …
novel or reinstating a pre-existing antitumor immune response. Most often …
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
F Aranda, E Vacchelli, A Eggermont, J Galon… - …, 2014 - europepmc.org
Immunostimulatory monoclonal antibodies (mAbs) exert antineoplastic effects by eliciting a
novel or reinstating a pre-existing antitumor immune response. Most often …
novel or reinstating a pre-existing antitumor immune response. Most often …
[PDF][PDF] Trial Watch
F Aranda, E Vacchelli, A Eggermont, J Galon… - 2014 - academia.edu
A large panel of monoclonal antibodies (mAbs) is currently approved by the US Food and
Drug Administration (FDA) and other international regulatory agencies, including the …
Drug Administration (FDA) and other international regulatory agencies, including the …
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
F Aranda, E Vacchelli, A Eggermont… - …, 2014 - pubmed.ncbi.nlm.nih.gov
Immunostimulatory monoclonal antibodies (mAbs) exert antineoplastic effects by eliciting a
novel or reinstating a pre-existing antitumor immune response. Most often …
novel or reinstating a pre-existing antitumor immune response. Most often …
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
F Aranda, E Vacchelli, A Eggermont, J Galon… - …, 2014 - europepmc.org
Immunostimulatory monoclonal antibodies (mAbs) exert antineoplastic effects by eliciting a
novel or reinstating a pre-existing antitumor immune response. Most often …
novel or reinstating a pre-existing antitumor immune response. Most often …
[PDF][PDF] Trial Watch
F Aranda, E Vacchelli, A Eggermont, J Galon… - academia.edu
A large panel of monoclonal antibodies (mAbs) is currently approved by the US Food and
Drug Administration (FDA) and other international regulatory agencies, including the …
Drug Administration (FDA) and other international regulatory agencies, including the …